DashboardAll companies
Run this on your own research
Healthcare · Diagnostics & Research

Illumina, Inc.

ILMNNASDAQ$269.42+$0.02 (+0.01%)Market closed

Price Chart

Daily

Key facts

Market Cap
$40.68B
P/E
49.1x
P/B
15.34x
ROE
33.4%

Illumina, Inc.

Healthcare · Diagnostics & Research · FY 2025

Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.

CEO
Mr. Jacob Thaysen Ph.D.
Employees
8,970

Company Statistics

Valuation

P/E
49.1x
P/B
15.34x
P/S
9.62x
EV/EBITDA
29.2x
P/FCF
44.9x

Margins

Gross
66.1%
EBITDA
33.8%
Operating
18.8%
Pre-Tax
25.0%
Net
19.6%

Returns

ROA
13.1%
ROE
33.4%
ROIC
18.3%

Growth (CAGR)

Rev 3Yr
−1.8%
Rev 5Yr
6.0%
Op Inc 3Yr
32.2%
Net Inc 3Yr
—

Financial Health

Cash & Cash Equivalents
$1.42B
Net Debt
$2.50B
Debt/Equity
144.0%
Interest Cov
—

Profile

Revenue
$4.34B
Shares Out
—
Public markets · Korea, US, Japanalpha-lenz.com · Core by Treasurer
Illumina, Inc. (ILMN) Stock Forecast 2026 $269.42 — Price, Financials & Analyst Targets | AlphaLenz